Bellerophon Therapeutics : Corporate Presentation

Bellerophon Therapeutics

Company Presentation I January 2023

Forward Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make due to a number of important factors, including risks and uncertainties relating to: INOpulse® not proving to be an effective treatment for COVID-19 or approved for marketing by the FDA, the timing and outcomes of our ongoing and expected clinical trials for our product candidates; our ability to successfully develop, commercialize and market any of our product candidates; our ability to obtain, maintain and enforce intellectual property rights; competition; our reliance on third parties; our ability to obtain necessary financing; and those risk factors discussed in the "Risk Factors" section and elsewhere in our most recent Form 10-K and other periodic filings we make with the SEC.

All forward-looking statements contained in this presentation reflect our current views with respect to future events. We assume no obligation, except as required by applicable law, to update any forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Bellerophon Therapeutics Overview | January 2023

2

Bellerophon Therapeutics (BLPH)

Late-stage

biotherapeutics

company developing inhaled nitric oxide (iNO) therapies to address significant unmet need in serious cardiopulmonary disorders

• INOpulse® inhaled nitric oxide (iNO) for chronic use
• • Targeted, pulsatile NO delivered via proprietary, portable, user-friendly device
  • Inhalational delivery to well ventilated areas of the lung overcomes drawbacks of systemic vasodilators
  • Positive results from multiple Phase 2 studies support mechanism of action
• Broad market opportunity in multiple cardiopulmonary disorders
• • Fibrotic interstitial lung disease (fILD) represents a broad underserved population >200K patients
  • Potential $1Bn+ markets in follow-on indications of pulmonary hypertension (PH) associated with sarcoidosis & chronic obstructive pulmonary disease (COPD)
  • IP protection up to 2039 before extensions
• Simplified de-risked regulatory pathway
• • NO approved for use in neonates (Ikaria); ability to leverage existing NDA
  • FDA agreement on MVPA primary endpoint in fILD Phase 3 REBUILD trial
• Highly experienced leadership team and solid financials
• • Unrestricted cash & equivalents $11.3 M1; no debt1; 12.2 million shares outstanding1,2
  • Additional $6M upfront payment from Baylor BioSciences for INOpulse® license rights in Greater China3

1. As of September 30, 2022; 2. Fully diluted; 3. $6M payable within 90 days of January 4, 2023, subject to certain closing	Bellerophon Therapeutics Overview | January 2023
conditions set forth in agreement

3

Highly Experienced Leadership Team with Expertise in Respiratory, Rare Diseases & Medical Devices

Peter Fernandes

Chief Executive Officer

Nicholas Laccona

Principal Financial &

Accounting Officer

Bobae Kim

VP, Regulatory Affairs & Quality Assurance

Parag Shah, Ph.D.

VP, Business Operations

Martin Dekker

VP, Device Engineering & Manufacturing

Bellerophon Therapeutics Overview | January 2023

4

Addressing Unmet Needs in Multiple Cardiopulmonary Diseases

INOpulse development pipeline

Indication	Phase 1	Phase 2	Phase 3	Current Status

fILD	REBUILD trial recruiting
Fibrotic Interstitial Lung
Underpinned by positive Phase 2 acute hemodynamic
Disease at risk of
trial (2020) & Phase 2 chronic trial (2019)
Pulmonary Hypertension
PH-SARC	Acute hemodynamic study completed
Pulmonary Hypertension
Positive study results reported end-2021
associated with Sarcoidosis
Phase 2 chronic use trial designed and cleared by FDA
PH-COPD	Phase 2b ready
Pulmonary Hypertension
Multiple phase 2 studies completed
associated with COPD
Phase 2b trial design finalized

Bellerophon Therapeutics Overview | January 2023

5